{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:08:05Z","timestamp":1791176885466,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.vaccine.2012.06.091","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T21:54:28Z","timestamp":1354226068000},"page":"F157-F167","source":"Crossref","is-referenced-by-count":99,"special_numbering":"S5","title":["Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries"],"prefix":"10.1016","volume":"30","author":[{"given":"Karen","family":"Canfell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrell","family":"Chesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini L.","family":"Kulasingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Berkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2012.06.091_bib0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cncr.22751","article-title":"Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing","volume":"111","author":"Schiffman","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 10","key":"10.1016\/j.vaccine.2012.06.091_bib0015","doi-asserted-by":"crossref","first-page":"K76","DOI":"10.1016\/j.vaccine.2008.06.009","article-title":"Modeling cervical cancer prevention in developed countries","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2012.06.091_bib0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000214924","article-title":"Economic evaluation of human papillomavirus vaccination in developed countries","volume":"12","author":"Brisson","year":"2009","journal-title":"Public Health Genomics"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2012.06.091_bib0030","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0035","unstructured":"Centers for Disease Control and Prevention. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011 Dec 23;60:1705-8."},{"key":"10.1016\/j.vaccine.2012.06.091_bib0040","unstructured":"PBAC. Pharmaceutical Benefits Advisory Committee (Australia): November 2011 PBAC Outcomes - Positive Recommendations. Canberra, Australia2011. Available at: http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/pbac-outcomes\/2011-11\/positive-recommendations (last accessed May 2012)."},{"issue":"11","key":"10.1016\/j.vaccine.2012.06.091_bib0045","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0050","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jnci\/djr053","article-title":"For cancers caused by HPV, two vaccines were just the beginning","volume":"103","author":"Peres","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0055","unstructured":"Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim J.J. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine, in press."},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10389-008-0228-3","article-title":"Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany","volume":"17","author":"Hillemanns","year":"2009","journal-title":"J Public Health (Oxf)."},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0070","doi-asserted-by":"crossref","first-page":"d5775","DOI":"10.1136\/bmj.d5775","article-title":"Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model","volume":"343","author":"Jit","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.vaccine.2012.06.091_bib0075","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0080","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Medicine"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2012.06.091_bib0085","article-title":"Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine."},{"issue":"7","key":"10.1016\/j.vaccine.2012.06.091_bib0090","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/aje\/kwk059","article-title":"Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty","volume":"165","author":"Van de Velde","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2012.06.091_bib0095","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1016\/j.vaccine.2008.02.039","article-title":"Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis","volume":"26","author":"Rogoza","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0100","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.09.031","article-title":"Health and economic impact associated with a quadrivalent HPV vaccine in Italy","volume":"112","author":"Mennini","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.vaccine.2012.06.091_bib0105","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.vaccine.2010.02.080","article-title":"The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy","volume":"28","author":"La Torre","year":"2010","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2012.06.091_bib0110","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1016\/j.vaccine.2008.07.098","article-title":"Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model","volume":"26","author":"Usher","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurpub\/ckp141","article-title":"A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme","volume":"20","author":"Dee","year":"2010","journal-title":"Eur J Public Health"},{"issue":"8","key":"10.1016\/j.vaccine.2012.06.091_bib0120","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1471-0528.2008.01743.x","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK","volume":"115","author":"Dasbach","year":"2008","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2012.06.091_bib0130","doi-asserted-by":"crossref","first-page":"F16","DOI":"10.1016\/j.vaccine.2008.02.040","article-title":"Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination","volume":"26","author":"Debicki","year":"2008","journal-title":"Vaccine."},{"issue":"4","key":"10.1016\/j.vaccine.2012.06.091_bib0135","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.24000","article-title":"HPV16\/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness","volume":"124","author":"Coupe","year":"2009","journal-title":"Int J Cancer"},{"issue":"35","key":"10.1016\/j.vaccine.2012.06.091_bib0140","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1016\/j.vaccine.2009.05.085","article-title":"Cost-effectiveness of prophylactic vaccination against human papillomavirus 16\/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands","volume":"27","author":"Rogoza","year":"2009","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2012.06.091_bib0145","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1016\/j.vaccine.2007.05.061","article-title":"Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands","volume":"25","author":"Boot","year":"2007","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2012.06.091_bib0150","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jnci\/djp183","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"101","author":"de Kok","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0155","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/djp372","article-title":"Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"102","author":"Coupe","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/djp374","article-title":"Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands: Response to Coupe","volume":"102","author":"de Kok","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/djp519","article-title":"Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"102","author":"Rozenbaum","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/djp524","article-title":"Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands: Response to Rozenbaum","volume":"102","author":"de Kok","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2010.09.030","article-title":"Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?","volume":"47","author":"de Kok","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1.","key":"10.1016\/j.vaccine.2012.06.091_bib0180","article-title":"Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France","volume":"24","author":"Bergeron","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0185","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1017\/S0266462309090217","article-title":"Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening","volume":"25","author":"Thiry","year":"2009","journal-title":"Int J Technol Assess Health Care."},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0190","doi-asserted-by":"crossref","DOI":"10.1185\/030079908X297826","article-title":"Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland","volume":"24","author":"Szucs","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","article-title":"A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer","volume":"56","author":"Demarteau","year":"2011","journal-title":"Int J Public Health"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0200","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14737167.8.5.491","article-title":"Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model","volume":"8","author":"Dasbach","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.vaccine.2012.06.091_bib0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3111\/13696990903546013","article-title":"The cost effectiveness of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in Hungary","volume":"13","author":"Dasbach","year":"2010","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0210","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1524-4733.2009.00512.x","article-title":"Age-based programs for vaccination against HPV","volume":"12","author":"Elbasha","year":"2009","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0215","first-page":"377","article-title":"Until which age should women Be vaccinated against HPV infection?","volume":"204","author":"Westra","year":"2011","journal-title":"Recommendation based on cost-effectiveness analyses. J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0220","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0266462310000085","article-title":"Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark","volume":"26","author":"Olsen","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"issue":"48","key":"10.1016\/j.vaccine.2012.06.091_bib0230","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1016\/j.vaccine.2011.09.055","article-title":"The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands","volume":"29","author":"Bogaards","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2012.06.091_bib0235","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/0003-4819-151-8-200910200-00007","article-title":"Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States","volume":"151","author":"Kim","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.vaccine.2012.06.091_bib0240","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.vaccine.2010.11.082","article-title":"Modelling patterns of clearance of HPV-16 infection and vaccination efficacy","volume":"29","author":"Baussano","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0245","doi-asserted-by":"crossref","unstructured":"Brisson M, van de Velde N, V, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011; 204(3):372-6.","DOI":"10.1093\/infdis\/jir285"},{"issue":"12","key":"10.1016\/j.vaccine.2012.06.091_bib0250","doi-asserted-by":"crossref","first-page":"e1001147","DOI":"10.1371\/journal.pmed.1001147","article-title":"Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models","volume":"8","author":"Bogaards","year":"2011","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0255","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","article-title":"Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland","volume":"96","author":"French","year":"2007","journal-title":"Br J Cancer"},{"issue":"48","key":"10.1016\/j.vaccine.2012.06.091_bib0260","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","article-title":"The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia","volume":"29","author":"Smith","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0265","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"issue":"42","key":"10.1016\/j.vaccine.2012.06.091_bib0270","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.vaccine.2012.06.091_bib0275","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2012.06.091_bib0280","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"37","key":"10.1016\/j.vaccine.2012.06.091_bib0285","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1016\/j.vaccine.2009.06.039","article-title":"Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria","volume":"27","author":"Zechmeister","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0290","unstructured":"Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. MMWR Morb Mortal Wkly Rep 2011 Aug 26;60(33):1117-23."},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0295","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1071\/SH10001","article-title":"Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia","volume":"8","author":"Gertig","year":"2011","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0300","doi-asserted-by":"crossref","first-page":"b4127","DOI":"10.1136\/bmj.b4127","article-title":"Should HPV vaccine be given to men?","volume":"339","author":"Castle","year":"2009","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0305","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2012.06.091_bib0310","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/QAI.0b013e31817aebfe","article-title":"Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study","volume":"48","author":"D'Souza","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"10.1016\/j.vaccine.2012.06.091_bib0315","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2012.06.091_bib0320","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/jnci\/djr319","article-title":"Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16\/18 vaccine","volume":"103","author":"Kreimer","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0325","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0330","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/infdis\/jir287","article-title":"Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs","volume":"204","author":"Castle","year":"2011","journal-title":"J Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2012.06.091_bib0335","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0340","series-title":"26th International papillomavirus conference","article-title":"Impact of disparities in HPV vaccine coverage on population-level effectiveness","author":"Brisson","year":"2010"},{"issue":"29","key":"10.1016\/j.vaccine.2012.06.091_bib0345","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0350","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2458-11-203","article-title":"Cost-effectiveness of different human papillomavirus vaccines in Singapore","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0355","doi-asserted-by":"crossref","first-page":"d7694","DOI":"10.1136\/bmj.d7694","article-title":"UK will use Gardasil in its HPV vaccination programme from next September","volume":"343","author":"Kmietowicz","year":"2011","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2012.06.091_bib0360","doi-asserted-by":"crossref","first-page":"A46","DOI":"10.1016\/j.vaccine.2008.10.085","article-title":"Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence","volume":"27","author":"Bonanni","year":"2009","journal-title":"Vaccine."},{"issue":"10","key":"10.1016\/j.vaccine.2012.06.091_bib0365","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0370","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"2","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"issue":"9686","key":"10.1016\/j.vaccine.2012.06.091_bib0375","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 10","key":"10.1016\/j.vaccine.2012.06.091_bib0380","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2012.06.091_bib0385","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3111\/13696998.2010.490481","article-title":"Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer","volume":"13","author":"Demarteau","year":"2010","journal-title":"J Med Econ"},{"issue":"3","key":"10.1016\/j.vaccine.2012.06.091_bib0390","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2011.01.029","article-title":"Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles","volume":"121","author":"Capri","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0395","series-title":"27th International Papillomavirus Conference and Clinical Workshop; September 17-22","article-title":"Modeling the effectiveness of the bivalent, quadrivalent and nonavalent vaccines","author":"Van de Velde","year":"2011"},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0400","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.bjc.6605528","article-title":"Predicted impact of vaccination against human papillomavirus 16\/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK","volume":"102","author":"Cuzick","year":"2010","journal-title":"Br J Cancer"},{"issue":"9783","key":"10.1016\/j.vaccine.2012.06.091_bib0405","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"48","key":"10.1016\/j.vaccine.2012.06.091_bib0410","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1016\/j.vaccine.2007.09.035","article-title":"Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S","volume":"25","author":"Kulasingam","year":"2007","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2012.06.091_bib0415","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.25211","article-title":"The health and economic effects of HPV DNA screening in The Netherlands","volume":"127","author":"Berkhof","year":"2010","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.vaccine.2012.06.091_bib0420","first-page":"1813","volume":"30","author":"Coupe","year":"2012","journal-title":"Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening."},{"issue":"5","key":"10.1016\/j.vaccine.2012.06.091_bib0425","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"10.1016\/j.vaccine.2012.06.091_bib0430","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1016\/j.ejca.2010.06.016","article-title":"Cost-effectiveness of human papillomavirus vaccination and screening in Spain","volume":"46","author":"Diaz","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0435","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1186\/1471-2458-10-734","article-title":"Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years","volume":"10","author":"Creighton","year":"2010","journal-title":"BMC Public Health."},{"issue":"12","key":"10.1016\/j.vaccine.2012.06.091_bib0440","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2012.06.091_bib0445","unstructured":"Health Protection Agency Immunisation Section: Annual HPV vaccine coverage in England in 2010\/2011: Routine programme for school year 8 females (12 to 13 years old). Available at: http:\/\/immunisation.dh.gov.uk\/annual-hpv-vaccine-coverage-in-england-in-201011-report\/ (last accessed March 2012)."},{"key":"10.1016\/j.vaccine.2012.06.091_bib0450","unstructured":"National Health and Medical Research Council (Australia): Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. Canberra, 2005."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T03:51:45Z","timestamp":1562385105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12009875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":90,"alternative-id":["S0264410X12009875"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.06.091","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}